Pfizer Signs a WW License Agreement with Pyxis to Develop and Commercialize Two ADC Candidates

 Pfizer Signs a WW License Agreement with Pyxis to Develop and Commercialize Two ADC Candidates

Pfizer Signs a WW License Agreement with Pyxis to Develop and Commercialize Two ADC Candidates

Shots:

  • Pfizer to receive an up front, equity in Pyxis and is eligible for development & commercial milestones as well as royalties on potential sales of ADCs
  • Pyxis gets a WW license to develop and commercialize PYX-201 and PYX-203. Pfizer will continue to support the development and advancement of ADCs portfolio via an equity investment
  • Additionally, Pyxis get the license to Pfizer’s ADC platform that will expand its ADC portfolio and further strengthen its developmental capabilities

Click here ­to­ read full press release/ article | Ref: Businesswire | Image: PRNewswire

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post